ES2418684B1 - Análogos formilados de xantocilinas como neuroprotectores - Google Patents

Análogos formilados de xantocilinas como neuroprotectores Download PDF

Info

Publication number
ES2418684B1
ES2418684B1 ES201230174A ES201230174A ES2418684B1 ES 2418684 B1 ES2418684 B1 ES 2418684B1 ES 201230174 A ES201230174 A ES 201230174A ES 201230174 A ES201230174 A ES 201230174A ES 2418684 B1 ES2418684 B1 ES 2418684B1
Authority
ES
Spain
Prior art keywords
formula
alkyl
compound
group
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201230174A
Other languages
English (en)
Spanish (es)
Other versions
ES2418684A1 (es
Inventor
María Del Carmen Ramos Martín
Sonia Campoy García
Javier Santos Burgos Muñoz
José Luis Adrio Fondevila
Javier Velasco Alvarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuron Biopharma SA
Original Assignee
Neuron Biopharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201230174A priority Critical patent/ES2418684B1/es
Application filed by Neuron Biopharma SA filed Critical Neuron Biopharma SA
Priority to CA2863820A priority patent/CA2863820A1/en
Priority to US14/377,143 priority patent/US9453004B2/en
Priority to BR112014018411A priority patent/BR112014018411A8/pt
Priority to AU2013217893A priority patent/AU2013217893A1/en
Priority to IN6536DEN2014 priority patent/IN2014DN06536A/en
Priority to PCT/ES2013/070065 priority patent/WO2013117789A2/es
Priority to JP2014556114A priority patent/JP2015513525A/ja
Priority to PL13711061T priority patent/PL2813222T3/pl
Priority to EP13711061.5A priority patent/EP2813222B1/en
Priority to MX2014009626A priority patent/MX2014009626A/es
Publication of ES2418684A1 publication Critical patent/ES2418684A1/es
Application granted granted Critical
Publication of ES2418684B1 publication Critical patent/ES2418684B1/es
Priority to IL233770A priority patent/IL233770A0/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/02—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/03—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungi isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/80—Penicillium
    • C12R2001/82—Penicillium chrysogenum

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES201230174A 2012-02-07 2012-02-07 Análogos formilados de xantocilinas como neuroprotectores Active ES2418684B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES201230174A ES2418684B1 (es) 2012-02-07 2012-02-07 Análogos formilados de xantocilinas como neuroprotectores
PL13711061T PL2813222T3 (pl) 2012-02-07 2013-02-06 Formylowane analogi ksantocyliny jako neuroprotektanty
BR112014018411A BR112014018411A8 (pt) 2012-02-07 2013-02-06 Composto de fórmula (i), composto de fórmula (ii), formulação farmacêutica, método para a preparação de um composto de fórmula (ii) e cepa de microrganismo
AU2013217893A AU2013217893A1 (en) 2012-02-07 2013-02-06 Formylated xanthocillin analogues as neuroprotectants
IN6536DEN2014 IN2014DN06536A (enExample) 2012-02-07 2013-02-06
PCT/ES2013/070065 WO2013117789A2 (es) 2012-02-07 2013-02-06 Análogos formilados de xantocilinas como neuroprotectores
CA2863820A CA2863820A1 (en) 2012-02-07 2013-02-06 Formylated xanthocillin analogues as neuroprotective agents
US14/377,143 US9453004B2 (en) 2012-02-07 2013-02-06 Formylated xanthocillin analogues as neuroprotective agents
EP13711061.5A EP2813222B1 (en) 2012-02-07 2013-02-06 Formylated xanthocillin analogues as neuroprotectants
MX2014009626A MX2014009626A (es) 2012-02-07 2013-02-06 Analogos formilados de xantocilinas como neuroprotectores.
JP2014556114A JP2015513525A (ja) 2012-02-07 2013-02-06 神経保護剤としてのホルミル化キサントシリン類似体
IL233770A IL233770A0 (en) 2012-02-07 2014-07-23 Xanthocillin analogs with formalin groups for use as neuroprotective agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230174A ES2418684B1 (es) 2012-02-07 2012-02-07 Análogos formilados de xantocilinas como neuroprotectores

Publications (2)

Publication Number Publication Date
ES2418684A1 ES2418684A1 (es) 2013-08-14
ES2418684B1 true ES2418684B1 (es) 2014-06-05

Family

ID=47913452

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230174A Active ES2418684B1 (es) 2012-02-07 2012-02-07 Análogos formilados de xantocilinas como neuroprotectores

Country Status (12)

Country Link
US (1) US9453004B2 (enExample)
EP (1) EP2813222B1 (enExample)
JP (1) JP2015513525A (enExample)
AU (1) AU2013217893A1 (enExample)
BR (1) BR112014018411A8 (enExample)
CA (1) CA2863820A1 (enExample)
ES (1) ES2418684B1 (enExample)
IL (1) IL233770A0 (enExample)
IN (1) IN2014DN06536A (enExample)
MX (1) MX2014009626A (enExample)
PL (1) PL2813222T3 (enExample)
WO (1) WO2013117789A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114181201B (zh) * 2020-09-15 2023-12-01 香港科技大学 作为针对各种神经退行性疾病的潜在治疗剂的新化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007191460A (ja) * 2005-04-14 2007-08-02 Nissan Chem Ind Ltd キサントシリン類縁体の製造方法
EP2241561A1 (en) * 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Neuroprotective, hypocholesterolemic and antiepileptic compound

Also Published As

Publication number Publication date
JP2015513525A (ja) 2015-05-14
IN2014DN06536A (enExample) 2015-06-26
WO2013117789A3 (es) 2013-11-28
ES2418684A1 (es) 2013-08-14
US9453004B2 (en) 2016-09-27
MX2014009626A (es) 2014-11-10
WO2013117789A2 (es) 2013-08-15
EP2813222A2 (en) 2014-12-17
AU2013217893A1 (en) 2014-09-25
BR112014018411A8 (pt) 2017-07-11
IL233770A0 (en) 2014-09-30
BR112014018411A2 (enExample) 2017-06-20
US20150011621A1 (en) 2015-01-08
EP2813222B1 (en) 2016-07-06
CA2863820A1 (en) 2013-08-15
PL2813222T3 (pl) 2017-01-31

Similar Documents

Publication Publication Date Title
Wang et al. A strategy of monitoring acetylcholinesterase and screening of natural inhibitors from Uncaria for Alzheimer's disease therapy based on near-infrared fluorescence probe
Zirihi et al. Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf
Basiri et al. Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives
DE69905616T2 (de) Verfahren und zusammensetzung zur behandlung und vorbeugung von mycobacterium infektionen
Sirimangkalakitti et al. Bromotyrosine alkaloids with acetylcholinesterase inhibitory activity from the Thai sponge Acanthodendrilla sp
Nguyen et al. Several herbal compounds in Okinawa plants directly inhibit the oncogenic/aging kinase PAK1
US20250376441A1 (en) Novel compound and pharmaceutical composition comprising same as active ingredient
Mori-Yasumoto et al. Leishmanicidal activities and cytotoxicities of bisnaphthoquinone analogues and naphthol derivatives from Burman Diospyros burmanica
KR100926798B1 (ko) 페리너스 속 버섯 또는 이노노투스 속 버섯의 균사체배양물로부터 분리된 히스피딘 유사체를 포함하는 항산화조성물
ES2418684B1 (es) Análogos formilados de xantocilinas como neuroprotectores
KR102001381B1 (ko) 신규한 ｏ-치환된 호노키올 유도체 화합물 및 이를 포함하는 퇴행성 질환의 예방 또는 치료용 약제학적 조성물
CN106749188B (zh) 一种n-(苄基哌啶基)-阿魏酰胺-o-烷基胺类化合物、制备方法及其用途
Rayavarapu et al. Synthesis of Putrescine Bisamides as Antimicrobial and Anti-Inflammatory Agents
CN104860847B (zh) 利凡斯的明和咖啡酸、阿魏酸的二聚体,其制备方法及其药物组合物
Đorđević et al. Immunomodulatory activity of marine natural products: Synthesis, spectral characterization and toxicity assessment of natural and related synthetic iodinated tyramides
EP3750904A1 (en) Therapeutic drug for neurodegenerative disease and application thereof
Hašanová Amaryllidaceae alkaloids of Narcissus poeticus var. recurvus and their implication to Alzheimer's disease and anticancer activity
US10287228B2 (en) Antimalarial agent, methods and uses thereof
KR101584528B1 (ko) 케르세틴-아미노산 접합체를 포함하는 항암 및 항생제 내성 억제효능을 보이는 조성물 및 그 방법
KR101603317B1 (ko) 케르세틴-아미노산 접합체를 포함하는 항암 및 항생제 내성 억제효능을 보이는 조성물 및 그 방법
KR100831757B1 (ko) 페리너스 속 버섯 또는 이노노투스 속 버섯의 균사체 배양물로부터 분리된 항산화 화합물 및 이를 포함하는 조성물
ES2402253A1 (es) Uso de oxoisoaporfinas en el tratamiento contra la leishmaniosis.
KR20130039916A (ko) 벤조히드록시메톡시칼콘을 유효성분으로 포함하는 항암제 조성물
JP2022524540A (ja) 抗酸化活性および神経保護活性を有する大環状化合物
US20130261133A1 (en) Therapeutic Compounds for Protozoal and Microbial Infections and Cancer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2418684

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140605